Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Ongoing health technology assessments related to in-vitro diagnostics by NICE in England

15 Jun 2021

The Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.

As of June 08, 2021, two DG concerned in-vitro diagnostics (IVDs) are in development with the scheduled publication date, and four assessments – without the scheduled date:

MedTech Innovation Briefing (MIB) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations.

As of June 08, 2021, three MIBs concerned IVDs are in development with the scheduled publication date, and one without the scheduled publication date:

  • Immunoscore for predicting the risk of relapse in patients with colon cancer by measuring the host immune response at the tumor site. The expected publication date is July 13, 2021;
  • MMprofiler a prognostic test to determine the risk of a multiple myeloma patient by classifying such patient into a "high" or "standard" risk group with the use of the well-validated SKY92 gene signature. The expected publication date is July 06, 2021;
  • clonoSEQ Assay for detecting and monitoring minimal residual disease (MRD) in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The expected publication date is August 10, 2021;
  • Trublood-prostate for triaging and diagnosing people with symptoms of prostate cancer. The publication date is not scheduled yet.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).